However, the ORR in patients with CLL treated with anti-CD19 CAR-T cells is substantially lower at about 30% [75], indicating that targeting the same antigen in different malignancies results in heterogeneous therapy responses probably due to the unique nature and microenvironment of different tumor types. The gene discussed is CD19; the disease is neoplasm.